Boehringer ingelheim and cue biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Ingelheim, germany, and boston, ma, usa, april 14, 2025 – boehringer ingelheim and cue biopharma, inc. (nasdaq: cue) today announced a strategic research collaboration and license agreement to develop and commercialize cue biopharma's cue-501 product candidate, a differentiated b cell depletion therapy for autoimmune diseases. cue biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the potential treatment of autoimmune and inflammatory diseases.
CUE Ratings Summary
CUE Quant Ranking